In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs

Exp Eye Res. 2020 Feb:191:107903. doi: 10.1016/j.exer.2019.107903. Epub 2020 Jan 3.

Authors

Affiliations

¹ Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
² Retina-Vitreous Associates Medical Group, Los Angeles, CA, USA.
³ Division of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, London, UK.
⁴ Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA. Electronic address: mkenney@hs.uci.edu.
⁵ Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; Department of Biomedical Engineering, University of California, Irvine, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Actins / genetics
Angiogenesis Inhibitors / pharmacology*
Angiogenic Proteins / genetics
Apoptosis
Apoptosis Regulatory Proteins / genetics
Bevacizumab / pharmacology
Carrier Proteins / genetics
Cell Line
Cell Survival
Ependymoglial Cells / drug effects*
Ependymoglial Cells / metabolism
Gene Expression / physiology*
Glial Fibrillary Acidic Protein / genetics
Humans
Inflammation / genetics
Membrane Potential, Mitochondrial / physiology
Oxidative Stress / genetics
Ranibizumab / pharmacology
Reactive Oxygen Species / metabolism
Real-Time Polymerase Chain Reaction
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins / pharmacology
Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

11-cis-retinal-binding protein
ACTA2 protein, human
Actins
Angiogenesis Inhibitors
Angiogenic Proteins
Apoptosis Regulatory Proteins
Carrier Proteins
GFAP protein, human
Glial Fibrillary Acidic Protein
Reactive Oxygen Species
Recombinant Fusion Proteins
VEGFA protein, human
Vascular Endothelial Growth Factor A
aflibercept
Bevacizumab
Receptors, Vascular Endothelial Growth Factor
Ranibizumab

Grants and funding